Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions
Cells · 04.02.2026 · 15 (3) · 295
DOI: 10.3390/cells15030295 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 04.02.2026. Verfasst von Ioanna Dagla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bioanalytical Laboratory, GAIA Research Center, The National Natural History Museum Goulandris, 145 62, Athens, Greece. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Neuroinflammatory Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the elderly. Among the diverse pathological features of AD, amyloid beta (Aβ) aggregation and neuroinflammation are recognized as central and interlinked mechanisms driving disease progression. This review focuses specifically on these two processes and highlights current pharmacological limitations in modifying disease pathology. Natural products such as curcumin, resveratrol, Ginkgo biloba, epigallocatechin gallate (EGCG), crocin, ashwagandha, and cannabidiol (CBD) have shown promising activity in modulating Aβ aggregation and neuroinflammatory pathways, offering multi-target neuroprotective effects in preclinical studies. However, their therapeutic application remains hindered by poor solubility, instability, rapid metabolism, and limited blood–brain barrier (BBB) permeability. To overcome these barriers, nanotechnology-based drug delivery systems—including polymeric nanoparticles, niosomes, solid lipid nanoparticles, and chitosan-based carriers—have emerged as effective strategies to enhance brain targeting, bioavailability, and pharmacological efficacy. We summarize the mechanistic insights and nanomedicine approaches related to these bioactives and discuss their potential in developing future disease-modifying therapies. By focusing on Aβ aggregation and neuroinflammation, this review provides a targeted perspective on the evolving role of natural compounds and nanocarriers in AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioanalytical Laboratory, GAIA Research Center, The National Natural History Museum Goulandris, 145 62, Athens, Greece.
- Laboratory of Analytical Chemistry, Faculty of Chemistry, National and Kapodistrian University of Athens, 157 71 Athens, Greece.
- Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece.
ORCID-Profile: Ioanna Dagla, Evagelos Gikas, Anthony Tsarbopoulos
Zitieren
APA
Dagla, I., Gkikas, F., Gikas, E., & Tsarbopoulos, A. (2026). Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions. Cells, 15(3), 295. https://doi.org/10.3390/cells15030295
Vancouver
Dagla I, Gkikas F, Gikas E, Tsarbopoulos A. Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions. Cells. 2026;15(3):295. doi:10.3390/cells15030295
BibTeX
@article{Dagla2026,
author = {Dagla, Ioanna and Gkikas, Faidon and Gikas, Evagelos and Tsarbopoulos, Anthony},
title = {Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions},
journal = {Cells},
year = {2026},
volume = {15},
number = {3},
pages = {295},
doi = {10.3390/cells15030295}
}
EUVIMED